Kim C. Ohaegbulam MD, PhD, Yilun Koethe MD, Alice Fung MD, FSAR, Skye C. Mayo MD, MPH, FACS, Aaron J. Grossberg MD, PhD, Emerson Y. Chen MD, Kaveh Sharzehi MD, MS, Adel Kardosh MD, PhD, Khashayar Farsad MD, PHD, Flavio G. Rocha MD, FACS, FSSO, Charles R. Thomas MD, Nima Nabavizadeh MD
{"title":"The multidisciplinary management of cholangiocarcinoma","authors":"Kim C. Ohaegbulam MD, PhD, Yilun Koethe MD, Alice Fung MD, FSAR, Skye C. Mayo MD, MPH, FACS, Aaron J. Grossberg MD, PhD, Emerson Y. Chen MD, Kaveh Sharzehi MD, MS, Adel Kardosh MD, PhD, Khashayar Farsad MD, PHD, Flavio G. Rocha MD, FACS, FSSO, Charles R. Thomas MD, Nima Nabavizadeh MD","doi":"10.1002/cncr.34541","DOIUrl":null,"url":null,"abstract":"<p>Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. However, its insidious onset, difficult diagnostics, and resultant advanced presentation render the majority of patients unresectable, highlighting the importance of early detection with novel biomarkers. Developing liver-directed therapies and emerging targeted therapeutics may offer improved survivability for patients with unresectable or advanced disease. In this article, the authors review the current multidisciplinary standards of care in resectable and unresectable cholangiocarcinoma, with an emphasis on novel biomarkers for early detection and nonsurgical locoregional therapy options.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"129 2","pages":"184-214"},"PeriodicalIF":6.1000,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.34541","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. However, its insidious onset, difficult diagnostics, and resultant advanced presentation render the majority of patients unresectable, highlighting the importance of early detection with novel biomarkers. Developing liver-directed therapies and emerging targeted therapeutics may offer improved survivability for patients with unresectable or advanced disease. In this article, the authors review the current multidisciplinary standards of care in resectable and unresectable cholangiocarcinoma, with an emphasis on novel biomarkers for early detection and nonsurgical locoregional therapy options.
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
